Invest in Infinite Potential

We are changing the paradigm of life sciences and the way we develop diagnostics, therapeutics and reproductive medicine

micro.png

NovelStem International Corp. focuses on the development and commercialization of diagnostic technology that can predict patients’  anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy

NovelStem was formerly known as Hollywood Media Corp. We changed our name to NovelStem International Corp. in September 2018 as a result of our business focus shift from a media business to stem cell-based diagnostics for cancer chemotherapies. NovelStem owns a legacy business interest, 50% interest in Netco Partners, which in turn owns "Net Force," a publishing book franchise.

NovelStem International Corp.

NS_logo_fin-4.png

NewStem

With its in-depth understanding of human stem cells and its proprietary technology of haploid human embryonic stem cells, NewStem intends to change the paradigm of life sciences and the way we develop diagnostics, therapeutics and reproductive medicine. NovelStem currently owns a 33% interest in NewStem.

Netco Partners

NovelStem owns a 50% interest in Netco Partners, a joint venture that owns the Net Force publishing franchise. Netco Partners has had success with the Net Force book series. Netco is relaunching Net Force, with the release of the first new book in 2019 under an agreement from HarperCollins.

Netforce_newbooks.png

Recent Press Releases

December 1

2020

NovelStem Increases NewStem Ownership to 33% as NewStem Prepares

for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares

April 21

2020

NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance; Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments

December 16

2019

NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic

May 8

2019

NovelStem announced today that its 50% owned Netco Partners unit has executed an agreement with Hanover Square Press, an imprint of HarperCollins, to relaunch the “Net Force” book series. 

Keep me updated on the latest happenings.

Add me to the NovelStem distribution list.

Thanks for subscribing. We will add you to the NSTM distribution list. 

Something went wrong. Please try again later, or email us directly to be put on the list. 

Recent Press Releases

December 1

2020

NovelStem Increases NewStem Ownership to 33% as NewStem Prepares

for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares

April 21

2020

NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance; Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments

December 16

2019

NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic

May 8

2019

NovelStem announced today that its 50% owned Netco Partners unit has executed an agreement with Hanover Square Press, an imprint of HarperCollins, to relaunch the “Net Force” book series. 

Recent Press Releases

December 1

2020

NovelStem Increases NewStem Ownership to 33% as NewStem Prepares

for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares

April 21

2020

NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance; Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments

December 16

2019

NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic

May 8

2019

NovelStem announced today that its 50% owned Netco Partners unit has executed an agreement with Hanover Square Press, an imprint of HarperCollins, to relaunch the “Net Force” book series.